“Discovering the Future of Cancer Treatment: Natera’s Exciting New Findings at the 2025 ASCO GI Symposium”
Natera Releases Abstracts for ASCO GI Symposium AUSTIN, Texas–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, has announced the release of the first set of abstracts from multiple studies that will be presented at the American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI) in January 2025. This symposium…